DB Securities says Aptabio's APX115 clinical results in acute kidney injury heighten expectations for technology export
Predicted impact: Low
Phase 2 trial success already reported in last 14 days; export hopes remain vague.
Aptabio Therapeutics압타바이오
293780 · KOSDAQ · ₩293780 · 압타바이오
₩5,310▼ ₩180 (3.28%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −26.15%
- Market cap
- ₩149B
- Enterprise value
- ₩141B
- P/E
- —
- P/B
- 3.5×
- Dividend yield
- 0.0%
- ROE
- −35.2%
- Net margin
- −312.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−51.2% from the high
₩3,870Today: ₩5,240 – ₩5,540₩10,890
Returns
- 1W−21.2%
- 1M−23.0%
- 3M+22.4%
- 6M−37.3%
- YTD−43.2%
- 1Y−26.1%
- Volume today
- 50,489
- 0.6× the 20-day average
- Traded today
- ₩269M
- Listed shares
- 28,093,405
- EPS (12 months)
- −₩529
- Earnings yield −10.0%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 32 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Brokerage says trial results raise expectations for a technology export. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-19.9% over the last month; the price is below its 20-day average.
- News impactSome2 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Aptabio Therapeutics stock overview
Aptabio Therapeutics (압타바이오, KRX: 293780) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean drug developer built on platform technologies, including oxidative stress modulation (NOX inhibition), CAF modulation, and aptamer-drug conjugate (Apta-DC) platforms, aiming to develop first-in-class drugs for global markets. Its shares closed at ₩5,310 on Oct 29, 2026, down 3.28% on the day, giving it a market value of ₩149B.
Key facts
- Market cap
- ₩149B
- Sector
- Biotech & Pharma
- Latest price change
- −3.28%
- As of
- Oct 29, 2026
- Main business
- The company is a Korean drug developer built on platform technologies, including oxidative stress modulation (NOX inhibition), CAF modulation, and aptamer-drug conjugate (Apta-DC) platforms, aiming to develop first-in-class drugs for global markets.
Quick answers about Aptabio Therapeutics
- What does Aptabio Therapeutics do?
- The company is a Korean drug developer built on platform technologies, including oxidative stress modulation (NOX inhibition), CAF modulation, and aptamer-drug conjugate (Apta-DC) platforms, aiming to develop first-in-class drugs for global markets. Its pipelines target diabetic nephropathy, contrast-induced nephropathy, MASH, macular degeneration, brain diseases, immuno-oncology, and refractory cancers such as pancreatic, blood, and liver cancer, with revenue mainly from technology fees and research reagent sales. It also runs new businesses in health functional food ODM, a premium pet care and pet products business, and a baby stroller and bag brand, selling products mainly in South Korea.
- What is the market cap of Aptabio Therapeutics?
- The market capitalisation of Aptabio Therapeutics was ₩149B at the close on Oct 29, 2026.
- Who are the largest shareholders of Aptabio Therapeutics?
- According to the latest official filings, the largest reported holders are Murim-Omega New Technology Investment Partnership No. 1 (4.85%, as of May 28, 2025); TS 2020-13 M&A Growth Partnership (4.59%, as of Oct 28, 2024); State Street(R) SPDR(R) S&P(R) International Small Cap ETF (0.06%, as of Jun 30, 2026).
- When is the next earnings report from Aptabio Therapeutics?
- Korean companies rarely announce results dates in advance. Based on when Aptabio Therapeutics filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Aptabio Therapeutics?
- Yes. The National Pension Service held 0.05% of Aptabio Therapeutics shares as of Dec 31, 2023.
Company profile
The company is a Korean drug developer built on platform technologies, including oxidative stress modulation (NOX inhibition), CAF modulation, and aptamer-drug conjugate (Apta-DC) platforms, aiming to develop first-in-class drugs for global markets. Its pipelines target diabetic nephropathy, contrast-induced nephropathy, MASH, macular degeneration, brain diseases, immuno-oncology, and refractory cancers such as pancreatic, blood, and liver cancer, with revenue mainly from technology fees and research reagent sales. It also runs new businesses in health functional food ODM, a premium pet care and pet products business, and a baby stroller and bag brand, selling products mainly in South Korea.
Written by AI from the company's latest annual report.
- Korean name
- 압타바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 이수진
- Founded
- Jul 2009
- Listed
- Jun 2019
- Listed shares
- 28,093,405
- Fiscal year ends
- Month 12
- Website
- www.aptabio.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent news
[Clinical Update] Aptabio hits primary endpoint in Phase 2 trial of APB-? (aptamer-based drug)
Predicted impact: Medium
Phase 2 primary endpoint result for a biotech; a prior item already reported the same milestone, so level lowered.
Aptabio's Aptazyme Achieves First Primary Endpoint in Global Phase 2 Trial
Predicted impact: Medium· Actual: −7.4% vs sector, volume 1.1× normal (5 trading days)
Global Phase 2 primary endpoint met; meaningful clinical milestone for a small biotech.
Recent filings
See allTitles in Korean until English translations are added.
Also known as: Aptabio Therapeutics / 압타바이오 / 293780 / KRX:293780
Source: KRX statistical information